United States Schizophrenia Drugs Market Report 2017

December 2017 | 103 pages | ID: UABE1F73F64EN
QYResearch

Abstracts

In this report, the United States Schizophrenia Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Schizophrenia Drugs in these regions, from 2012 to 2022 (forecast).

United States Schizophrenia Drugs market competition by top manufacturers/players, with Schizophrenia Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Johnson & Johnson
• Bristol-Myers Squibb/ Otsuka Pharma
• AstraZeneca
• Sumitomo Dainippon
• Eli Lilly
• Alkermes
• Vanda Pharma
• Allergan
• Pfizer

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Second-Generation Antipsychotics
• Third-Generation Antipsychotics
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Oral Antipsychotics
• Injectable Antipsychotics

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Schizophrenia Drugs Market Report 2017

1 SCHIZOPHRENIA DRUGS OVERVIEW

1.1 Product Overview and Scope of Schizophrenia Drugs
1.2 Classification of Schizophrenia Drugs by Product Category
  1.2.1 United States Schizophrenia Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Schizophrenia Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Second-Generation Antipsychotics
  1.2.4 Third-Generation Antipsychotics
  1.2.5 Others
1.3 United States Schizophrenia Drugs Market by Application/End Users
  1.3.1 United States Schizophrenia Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Oral Antipsychotics
  1.3.3 Injectable Antipsychotics
1.4 United States Schizophrenia Drugs Market by Region
  1.4.1 United States Schizophrenia Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Schizophrenia Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Schizophrenia Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Schizophrenia Drugs Status and Prospect (2012-2022)
  1.4.5 New England Schizophrenia Drugs Status and Prospect (2012-2022)
  1.4.6 The South Schizophrenia Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Schizophrenia Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Schizophrenia Drugs (2012-2022)
  1.5.1 United States Schizophrenia Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Schizophrenia Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES SCHIZOPHRENIA DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Schizophrenia Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Schizophrenia Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Schizophrenia Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Schizophrenia Drugs Market Competitive Situation and Trends
  2.4.1 United States Schizophrenia Drugs Market Concentration Rate
  2.4.2 United States Schizophrenia Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Schizophrenia Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES SCHIZOPHRENIA DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Schizophrenia Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Schizophrenia Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Schizophrenia Drugs Price by Region (2012-2017)

4 UNITED STATES SCHIZOPHRENIA DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Schizophrenia Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Schizophrenia Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Schizophrenia Drugs Price by Type (2012-2017)
4.4 United States Schizophrenia Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES SCHIZOPHRENIA DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Schizophrenia Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Schizophrenia Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES SCHIZOPHRENIA DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Johnson & Johnson
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Schizophrenia Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Johnson & Johnson Schizophrenia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Bristol-Myers Squibb/ Otsuka Pharma
  6.2.2 Schizophrenia Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Bristol-Myers Squibb/ Otsuka Pharma Schizophrenia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 AstraZeneca
  6.3.2 Schizophrenia Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 AstraZeneca Schizophrenia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Sumitomo Dainippon
  6.4.2 Schizophrenia Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Sumitomo Dainippon Schizophrenia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Eli Lilly
  6.5.2 Schizophrenia Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Eli Lilly Schizophrenia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Alkermes
  6.6.2 Schizophrenia Drugs Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Alkermes Schizophrenia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Vanda Pharma
  6.7.2 Schizophrenia Drugs Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Vanda Pharma Schizophrenia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Allergan
  6.8.2 Schizophrenia Drugs Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Allergan Schizophrenia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Pfizer
  6.9.2 Schizophrenia Drugs Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Pfizer Schizophrenia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview

7 SCHIZOPHRENIA DRUGS MANUFACTURING COST ANALYSIS

7.1 Schizophrenia Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Schizophrenia Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Schizophrenia Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Schizophrenia Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES SCHIZOPHRENIA DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Schizophrenia Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Schizophrenia Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Schizophrenia Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Schizophrenia Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Schizophrenia Drugs
Figure United States Schizophrenia Drugs Market Size (Units) by Type (2012-2022)
Figure United States Schizophrenia Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Second-Generation Antipsychotics Product Picture
Figure Third-Generation Antipsychotics Product Picture
Figure Others Product Picture
Figure United States Schizophrenia Drugs Market Size (Units) by Application (2012-2022)
Figure United States Sales Market Share of Schizophrenia Drugs by Application in 2016
Figure Oral Antipsychotics Examples
Table Key Downstream Customer in Oral Antipsychotics
Figure Injectable Antipsychotics Examples
Table Key Downstream Customer in Injectable Antipsychotics
Figure United States Schizophrenia Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Schizophrenia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Schizophrenia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Schizophrenia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Schizophrenia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Schizophrenia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Schizophrenia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Schizophrenia Drugs Sales (Units) and Growth Rate (2012-2022)
Figure United States Schizophrenia Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Schizophrenia Drugs Market Major Players Product Sales Volume (Units) (2012-2017)
Table United States Schizophrenia Drugs Sales (Units) of Key Players/Suppliers (2012-2017)
Table United States Schizophrenia Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Schizophrenia Drugs Sales Share by Players/Suppliers
Figure 2017 United States Schizophrenia Drugs Sales Share by Players/Suppliers
Figure United States Schizophrenia Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Schizophrenia Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Schizophrenia Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Schizophrenia Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Schizophrenia Drugs Revenue Share by Players/Suppliers
Table United States Market Schizophrenia Drugs Average Price (K USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Schizophrenia Drugs Average Price (K USD/Unit) of Key Players/Suppliers in 2016
Figure United States Schizophrenia Drugs Market Share of Top 3 Players/Suppliers
Figure United States Schizophrenia Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Schizophrenia Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Schizophrenia Drugs Product Category
Table United States Schizophrenia Drugs Sales (Units) by Region (2012-2017)
Table United States Schizophrenia Drugs Sales Share by Region (2012-2017)
Figure United States Schizophrenia Drugs Sales Share by Region (2012-2017)
Figure United States Schizophrenia Drugs Sales Market Share by Region in 2016
Table United States Schizophrenia Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Schizophrenia Drugs Revenue Share by Region (2012-2017)
Figure United States Schizophrenia Drugs Revenue Market Share by Region (2012-2017)
Figure United States Schizophrenia Drugs Revenue Market Share by Region in 2016
Table United States Schizophrenia Drugs Price (K USD/Unit) by Region (2012-2017)
Table United States Schizophrenia Drugs Sales (Units) by Type (2012-2017)
Table United States Schizophrenia Drugs Sales Share by Type (2012-2017)
Figure United States Schizophrenia Drugs Sales Share by Type (2012-2017)
Figure United States Schizophrenia Drugs Sales Market Share by Type in 2016
Table United States Schizophrenia Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Schizophrenia Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Schizophrenia Drugs by Type (2012-2017)
Figure Revenue Market Share of Schizophrenia Drugs by Type in 2016
Table United States Schizophrenia Drugs Price (K USD/Unit) by Types (2012-2017)
Figure United States Schizophrenia Drugs Sales Growth Rate by Type (2012-2017)
Table United States Schizophrenia Drugs Sales (Units) by Application (2012-2017)
Table United States Schizophrenia Drugs Sales Market Share by Application (2012-2017)
Figure United States Schizophrenia Drugs Sales Market Share by Application (2012-2017)
Figure United States Schizophrenia Drugs Sales Market Share by Application in 2016
Table United States Schizophrenia Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Schizophrenia Drugs Sales Growth Rate by Application (2012-2017)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Schizophrenia Drugs Sales (Units), Revenue (Million USD), Price (K USD/Unit) and Gross Margin (2012-2017)
Figure Johnson & Johnson Schizophrenia Drugs Sales Growth Rate (2012-2017)
Figure Johnson & Johnson Schizophrenia Drugs Sales Market Share in United States (2012-2017)
Figure Johnson & Johnson Schizophrenia Drugs Revenue Market Share in United States (2012-2017)
Table Bristol-Myers Squibb/ Otsuka Pharma Basic Information List
Table Bristol-Myers Squibb/ Otsuka Pharma Schizophrenia Drugs Sales (Units), Revenue (Million USD), Price (K USD/Unit) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb/ Otsuka Pharma Schizophrenia Drugs Sales Growth Rate (2012-2017)
Figure Bristol-Myers Squibb/ Otsuka Pharma Schizophrenia Drugs Sales Market Share in United States (2012-2017)
Figure Bristol-Myers Squibb/ Otsuka Pharma Schizophrenia Drugs Revenue Market Share in United States (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca Schizophrenia Drugs Sales (Units), Revenue (Million USD), Price (K USD/Unit) and Gross Margin (2012-2017)
Figure AstraZeneca Schizophrenia Drugs Sales Growth Rate (2012-2017)
Figure AstraZeneca Schizophrenia Drugs Sales Market Share in United States (2012-2017)
Figure AstraZeneca Schizophrenia Drugs Revenue Market Share in United States (2012-2017)
Table Sumitomo Dainippon Basic Information List
Table Sumitomo Dainippon Schizophrenia Drugs Sales (Units), Revenue (Million USD), Price (K USD/Unit) and Gross Margin (2012-2017)
Figure Sumitomo Dainippon Schizophrenia Drugs Sales Growth Rate (2012-2017)
Figure Sumitomo Dainippon Schizophrenia Drugs Sales Market Share in United States (2012-2017)
Figure Sumitomo Dainippon Schizophrenia Drugs Revenue Market Share in United States (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly Schizophrenia Drugs Sales (Units), Revenue (Million USD), Price (K USD/Unit) and Gross Margin (2012-2017)
Figure Eli Lilly Schizophrenia Drugs Sales Growth Rate (2012-2017)
Figure Eli Lilly Schizophrenia Drugs Sales Market Share in United States (2012-2017)
Figure Eli Lilly Schizophrenia Drugs Revenue Market Share in United States (2012-2017)
Table Alkermes Basic Information List
Table Alkermes Schizophrenia Drugs Sales (Units), Revenue (Million USD), Price (K USD/Unit) and Gross Margin (2012-2017)
Figure Alkermes Schizophrenia Drugs Sales Growth Rate (2012-2017)
Figure Alkermes Schizophrenia Drugs Sales Market Share in United States (2012-2017)
Figure Alkermes Schizophrenia Drugs Revenue Market Share in United States (2012-2017)
Table Vanda Pharma Basic Information List
Table Vanda Pharma Schizophrenia Drugs Sales (Units), Revenue (Million USD), Price (K USD/Unit) and Gross Margin (2012-2017)
Figure Vanda Pharma Schizophrenia Drugs Sales Growth Rate (2012-2017)
Figure Vanda Pharma Schizophrenia Drugs Sales Market Share in United States (2012-2017)
Figure Vanda Pharma Schizophrenia Drugs Revenue Market Share in United States (2012-2017)
Table Allergan Basic Information List
Table Allergan Schizophrenia Drugs Sales (Units), Revenue (Million USD), Price (K USD/Unit) and Gross Margin (2012-2017)
Figure Allergan Schizophrenia Drugs Sales Growth Rate (2012-2017)
Figure Allergan Schizophrenia Drugs Sales Market Share in United States (2012-2017)
Figure Allergan Schizophrenia Drugs Revenue Market Share in United States (2012-2017)
Table Pfizer Basic Information List
Table Pfizer Schizophrenia Drugs Sales (Units), Revenue (Million USD), Price (K USD/Unit) and Gross Margin (2012-2017)
Figure Pfizer Schizophrenia Drugs Sales Growth Rate (2012-2017)
Figure Pfizer Schizophrenia Drugs Sales Market Share in United States (2012-2017)
Figure Pfizer Schizophrenia Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Schizophrenia Drugs
Figure Manufacturing Process Analysis of Schizophrenia Drugs
Figure Schizophrenia Drugs Industrial Chain Analysis
Table Raw Materials Sources of Schizophrenia Drugs Major Players/Suppliers in 2016
Table Major Buyers of Schizophrenia Drugs
Table Distributors/Traders List
Figure United States Schizophrenia Drugs Sales Volume (Units) and Growth Rate Forecast (2017-2022)
Figure United States Schizophrenia Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Schizophrenia Drugs Price (K USD/Unit) Trend Forecast (2017-2022)
Table United States Schizophrenia Drugs Sales Volume (Units) Forecast by Type (2017-2022)
Figure United States Schizophrenia Drugs Sales Volume (Units) Forecast by Type (2017-2022)
Figure United States Schizophrenia Drugs Sales Volume (Units) Forecast by Type in 2022
Table United States Schizophrenia Drugs Sales Volume (Units) Forecast by Application (2017-2022)
Figure United States Schizophrenia Drugs Sales Volume (Units) Forecast by Application (2017-2022)
Figure United States Schizophrenia Drugs Sales Volume (Units) Forecast by Application in 2022
Table United States Schizophrenia Drugs Sales Volume (Units) Forecast by Region (2017-2022)
Table United States Schizophrenia Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Schizophrenia Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Schizophrenia Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources